Phase III IMpower150 Study Showed Genentechs TECENTRIQ and Avastin Plus Carboplatin and Paclitaxel Helped People With a Specific Type of Metastatic Lung Cancer Live Significantly Longer Compared to Avastin Plus Carboplatin and Paclitaxel

A survival advantage for the TECENTRIQ and Avastin combination regimen was observed in all prespecified exploratory patient subgroups analyzed including people with EGFR and ALK mutations liver metastases and those with varying lev...